Alkermes FY2022 revenue $1.11B, GAAP loss per share $0.97; guides FY2023 revenue $1.13-1.25B

Alkermes plc.

2022-FY EPS reported -$0.97 revenue$1,111,795,000

Q4 2022 total revenues $304.7M, GAAP net loss $0.17/share, non-GAAP diluted EPS $0.14.
FY2022 proprietary net sales: VIVITROL $379.5M (+10%), ARISTADA $302.1M (+10%), LYBALVI $96.0M (first full year).
FY2023 guidance: revenue $1.13-$1.25B, GAAP loss per share ($0.96)-($1.20), non-GAAP diluted EPS $0.00-$0.23.
New long-term profitability targets: FY2024 non-GAAP net income 25% of revenue, EBITDA margin 20%; FY2025 30% and 25%.
Plans to separate oncology business in H2 2023; arbitration with Janssen ongoing, interim award in company's favor.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alkermes plc. reported the quarter ended December 31, 2022 results: revenue $304.7 million, net income $28.3 million, EPS $0.17.

Period: the quarter ended December 31, 2022
Revenue: $304.7 million
Net income: $28.3 million
EPS: $0.17
Result: reported results

Exact text from the filing

• Total revenues for the quarter were $304.7 million, compared to $324.5 million for the same period in the prior year. • Net sales of proprietary products for the quarter were $216.1 million, compared to $178.9 million for the same period in the prior year. o Net sales of VIVITROL were $102.0 million, compared to $92.0 million for the same period in the prior year, representing an increase of approximately 11%. o Net sales of ARISTADA 1 were $79.2 million, compared to $78.7 million for the same period in the prior year, representing an increase of approximately 1%. o Net sales of LYBALVI were $34.9 million, compared to $8.2 million for the same period in the prior year, following commercial launch in October 2021. • Total operating expenses for the quarter were $325.3 million, compared to $322.1 million for the same period in the prior year. • Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $28.3 million for the quarter, or a basic and

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Alkermes plc. updated its the year ending December 31, 2023 guidance (initiated).

Period: the year ending December 31, 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

On February 16, 2023, Alkermes plc (the “Company”) announced financial results for the three months and year ended December 31, 2022 and financial expectations for the year ending December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Alkermes plc. reported the year ended December 31, 2022 results: revenue $1.11 billion, net income $158.3 million, EPS $0.97.

Period: the year ended December 31, 2022
Revenue: $1.11 billion
Net income: $158.3 million
EPS: $0.97
Result: reported results

Exact text from the filing

— Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 —

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0001564590-23-001975

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.